{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T21:16:47Z","timestamp":1777238207513,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd011343","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T00:00:00Z","timestamp":1490659200000}}],"reference-count":177,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011343.pub2","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T16:29:33Z","timestamp":1492014573000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacological interventions for primary sclerosing cholangitis"],"prefix":"10.1002","volume":"2017","author":[{"given":"Francesca","family":"Saffioti","sequence":"first","affiliation":[{"name":"Royal Free Hospital and the UCL Institute of Liver and Digestive Health; Sheila Sherlock Liver Centre; Pond Street Hampstead London UK NW3 2QG"},{"name":"University of Messina; Department of Clinical and Experimental Medicine, Division of Clinical and Molecular Hepatology; Via Consolare Valeria, 1 Messina Messina Italy 98125"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurinchi Selvan","family":"Gurusamy","sequence":"additional","affiliation":[{"name":"Royal Free Campus, UCL Medical School; Department of Surgery; Royal Free Hospital Rowland Hill Street London UK NW3 2PF"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Hawkins","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine; HSRP; Keppel Street London UK WC1E 7HT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare D","family":"Toon","sequence":"additional","affiliation":[{"name":"West Sussex County Council; Public Health & Social Research Unit; The Grange, County Hall Campus Tower Street Chichester West Sussex UK PO19 1QT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Tsochatzis","sequence":"additional","affiliation":[{"name":"Royal Free Hospital and the UCL Institute of Liver and Digestive Health; Sheila Sherlock Liver Centre; Pond Street Hampstead London UK NW3 2QG"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R","family":"Davidson","sequence":"additional","affiliation":[{"name":"Royal Free Campus, UCL Medical School; Department of Surgery; Royal Free Hospital Rowland Hill Street London UK NW3 2PF"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Thorburn","sequence":"additional","affiliation":[{"name":"Royal Free Hospital and the UCL Institute of Liver and Digestive Health; Sheila Sherlock Liver Centre; Pond Street Hampstead London UK NW3 2QG"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,28]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0168-8278(86)80155-6","article-title":"Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study","volume":"3","author":"Allison","year":"1986","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0002|cit2","first-page":"A1146","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a randomised double-blind placebo-controlled trial","volume":"110","author":"Bansi","year":"1996","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011343.pub2-BIB0003|cit3","first-page":"A54","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a randomised double-blind, placebo-controlled trial","volume":"38","author":"Bansi","year":"1996","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0005|cit4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.1840160315","article-title":"Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial","volume":"16","author":"Beuers","year":"1992","journal-title":"Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD011343.pub2-BIB0004|cit5","first-page":"64a","article-title":"Effect of ursodeoxycholic acid in primary sclerosing cholangitis: a controlled trial [abstract]","volume":"14","author":"Beuers","year":"1991","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0006|cit6","unstructured":"Spengler U Beuers U Kruis W Ursodeoxycholic acid in primary sclerosing cholangitis Bile Acids and the Hepatobiliary System From Basic Science to Clinical Practice Proceedings of Falk Symposium 68th Held in Basel, Switzerland, October 12-14, 1992. 1993 316 22"},{"issue":"8","key":"10.1002\/14651858.CD011343.pub2-BIB0007|cit7","first-page":"760","article-title":"Tolerance and efficacy of a high-dose treatment with urosodeoxycholic acid in primary sclerosing cholangitis. A double-blind randomised, placebo-controlled dose-finding study","volume":"44","author":"Beuers","year":"2006","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011343.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1016\/S0168-8278(06)80635-5","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective","volume":"44","author":"Cullen","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011343.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2007.12.023","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective","volume":"48","author":"Cullen","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD011343.pub2-BIB0010|cit10","first-page":"1472","article-title":"Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period","volume":"43","author":"Maria","year":"1996","journal-title":"Hepatogastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD011343.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.20457","article-title":"Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial","volume":"40","author":"Farkkila","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011343.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MCG.0b013e3181662426","article-title":"A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis","volume":"42","author":"Hommes","year":"2008","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/0016-5085(94)90610-6","article-title":"A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis","volume":"106","author":"Knox","year":"1994","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD011343.pub2-BIB0014|cit14","first-page":"1205","article-title":"Randomized trial of penicillamine in primary sclerosing cholangitis","volume":"6","author":"LaRusso","year":"1986","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/0016-5085(88)90180-1","article-title":"Prospective trial of penicillamine in primary sclerosing cholangitis","volume":"95","author":"LaRusso","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0016|cit16","first-page":"509A","article-title":"Long-term follow-up of a multicenter, randomized controlled trial of ursodeoxycholic acid in primary sclerosing cholangitis","volume":"62","author":"Hilscher","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0017|cit17","first-page":"A1252","article-title":"A randomized trial of ursodeoxycholic acid (UDCA) in the treatment of primary sclerosing cholangitis (PSC)","volume":"110","author":"Lindor","year":"1996","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD011343.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group","volume":"336","author":"Lindor","year":"1997","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2003.50156","article-title":"Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"124","author":"Pardi","year":"2003","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD011343.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"Eaton","year":"2011","journal-title":"The American Journal of Gastroenterology"},{"issue":"4Suppl","key":"10.1002\/14651858.CD011343.pub2-BIB0021|cit21","first-page":"378a","article-title":"Randomized, double-blind controlled trial of high-dose ursodeoxycholic acid (UCDA) for primary sclerosing cholangitis (PSC)","volume":"48","author":"Lindor","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hep.23631","article-title":"Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression","volume":"52","author":"Sinakos","year":"2010","journal-title":"Hepatology"},{"issue":"2 Pt 2","key":"10.1002\/14651858.CD011343.pub2-BIB0024|cit24","first-page":"92a","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis: a double-blind placebo controlled trial","volume":"16","author":"Lo","year":"1992","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0025|cit25","first-page":"A1335","article-title":"High dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): results after two years of a randomised double-blind, placebo-controlled trial","volume":"112","author":"Mitchell","year":"1997","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011343.pub2-BIB0026|cit26","first-page":"A29","article-title":"High dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): results after two years of a randomised double-blind, placebo-controlled trial","volume":"40","author":"Mitchell","year":"1997","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","article-title":"A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis","volume":"121","author":"Mitchell","year":"2001","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/0016-5085(95)90220-1","article-title":"Colchicine treatment of primary sclerosing cholangitis","volume":"108","author":"Olsson","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0029|cit29","first-page":"247a","article-title":"A reduction in alkaline phosphatase levels is associated to improved prognosis in primary sclerosing cholangitis: a 14 year follow up of the Scandinavian ursodeoxycholic acid trial","volume":"56","author":"Lindstrom","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2036.2011.04966.x","article-title":"High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia","volume":"35","author":"Lindstrom","year":"2012","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD011343.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011343.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0168-8278(04)90551-X","article-title":"Five-year treatment with high-dose UDCA in PSC","volume":"40","author":"Olsson","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011343.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0168-8278(98)80702-2","article-title":"Methotrexate for treatment of primary sclerosing cholangitis","volume":"28","author":"Rasmussen","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/gut.34.2.242","article-title":"Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin","volume":"34","author":"Sandborn","year":"1993","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0036|cit36","unstructured":"Wiesner RH Steiner B LaRusso NF Lindor KD Baldus WP A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis Hepatology 1991 63a"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011343.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"204a","DOI":"10.1016\/S0270-9139(03)80143-X","article-title":"A prospective, randomized controlled pilot study of ursodeoxycholic acid (UDCA) combined with mycophenolate mofetil (MMF) in the treatment of primary sclerosing cholangitis","volume":"38","author":"Sterlin","year":"2003","journal-title":"Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD011343.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2036.2004.02214.x","article-title":"A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis","volume":"20","author":"Sterling","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0039|cit39","first-page":"602","article-title":"Treatment of primary sclerosing cholangitis with ursodeoxycholic acid: first results of a controlled study","volume":"10","author":"Stiehl","year":"1989","journal-title":"Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011343.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"S1069","DOI":"10.1016\/S0016-5085(16)33611-3","article-title":"Long-term outcomes following a randomized study of oral antibiotics in primary sclerosing cholangitis","volume":"150","author":"Tabibian","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD011343.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011343.pub2-BIB0042|cit42","first-page":"111A","article-title":"Norursodeoxycholic acid (NORUDCA) improves cholestasis in primary sclerosing cholangitis (PSC) independent of ursodeoxycholic acid (UDCA) pre-treatment and response","volume":"64","author":"Trauner","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0043|cit43","first-page":"189","article-title":"Treatment of primary sclerosing cholangitis: drug, endoscopic, combined or no treatment at all?","volume":"36","author":"Beuers","year":"1998","journal-title":"Zeitschrift f\u00fcr Gastroenterologie"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/1-4020-2913-6_30","article-title":"High-dose ursodeoxycholic acid in the management of primary sclerosing cholangitis","volume":"141","author":"Chapman","year":"2005","journal-title":"Bile Acid Biology and Its Therapeutic Implications"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.23174","article-title":"High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?","volume":"50","author":"Chapman","year":"2009","journal-title":"Hepatology"},{"issue":"18","key":"10.1002\/14651858.CD011343.pub2-BIB0046|cit46","first-page":"7","article-title":"Primary sclerosing cholangitis. Ursodeoxycholic acid is without clinical effect","volume":"115","author":"Eisenburg","year":"1997","journal-title":"Fortschritte der Medizin"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0016-5085(92)91138-T","article-title":"New treatment for primary sclerosing cholangitis: promising results with ursodiol","volume":"103","author":"Fromm","year":"1992","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0016-5085(92)90128-L","article-title":"Primary sclerosing cholangitis: is medical therapy on the way?","volume":"102","author":"Goldberg","year":"1992","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0016-5085(93)91042-G","article-title":"Promises, promises: ursodeoxycholic acid for primary sclerosing cholangitis","volume":"104","author":"Gross","year":"1993","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD011343.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1572-0241.2001.03777.x","article-title":"High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis","volume":"96","author":"Harnois","year":"2001","journal-title":"The American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0168-8278(00)00093-3","article-title":"A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis","volume":"34","author":"Hay","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD011343.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1365-2036.2011.04863.x","article-title":"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis","volume":"34","author":"Imam","year":"2011","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kuiper","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s005350300053","article-title":"Efficacy of bezafibrate in a patient with primary sclerosing cholangitis","volume":"38","author":"Kurihara","year":"2003","journal-title":"Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00004836-200301000-00029","article-title":"Use of mycophenolate mofetil in the treatment of primary sclerosing cholangitis","volume":"36","author":"Lankarani","year":"2003","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD011343.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1365-2036.2005.02451.x","article-title":"Mycophenolate mofetil for the treatment of primary sclerosing cholangitis","volume":"21","author":"Lankarani","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0057|cit57","first-page":"141","article-title":"Long-term experience with ursodeoxycholic acid for patients with primary biliary cirrhosis and primary sclerosing cholangitis","author":"Lindor","year":"1995","journal-title":"International Falk Workshop Bile Acids in Liver Diseases"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/1-4020-2913-6_29","article-title":"Dose effect of ursodeoxycholic acid used in the treatment of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"141","author":"Lindor","year":"2005","journal-title":"Bile Acid Biology and Its Therapeutic Implications"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4020-9644-0_34","article-title":"Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume-title":"Bile Acid Biology and Therapeutic Actions","volume":"165","author":"Lindor","year":"2009"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011343.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2008.02.002","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"48","author":"Silveira","year":"2008","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0062|cit62","first-page":"316","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis","author":"Spengler","year":"1993","journal-title":"Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Proceedings of Falk Symposium 68"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0063|cit63","first-page":"136","article-title":"Treatment of primary sclerosing cholangitis with ursodeoxycholic acid","volume":"24","author":"Stiehl","year":"1989","journal-title":"Zeitschrift fur Gastroenterologie - Verhandlungsband"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0064|cit64","first-page":"136","article-title":"[Treatment of primary sclerosing cholangitis with ursodeoxycholic acid]","volume":"24","author":"Stiehl","year":"1989","journal-title":"Z Gastroenterol Verh"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/00365529409103626","article-title":"Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis","volume":"204","author":"Stiehl","year":"1994","journal-title":"Scandinavian Journal of Gastroenterology. Supplement"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0168-8278(05)80467-2","article-title":"Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period","volume":"20","author":"Stiehl","year":"1994","journal-title":"Journal of Hepatology"},{"issue":"37","key":"10.1002\/14651858.CD011343.pub2-BIB0067|cit67","first-page":"305","article-title":"Effects of ursodeoxycholic acid in patients with primary sclerosing cholangitis","author":"Stiehl","year":"1991","journal-title":"Bile Acids as Therapeutic Agents. From Basic Science to Clinical Practice. Proceedings of Falk Symposium 58"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0068|cit68","first-page":"178","article-title":"Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis","volume":"28","author":"Stiehl","year":"1996","journal-title":"Italian Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0069|cit69","first-page":"340","article-title":"Rifampin as antipruritic agent in primary sclerosing cholangitis","volume":"84","author":"Tabibian","year":"1989","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00535-005-1758-x","article-title":"Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis","volume":"41","author":"Tada","year":"2006","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-230X-4-13","article-title":"Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]","volume":"4","author":"ter Borg","year":"2004","journal-title":"BMC Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD011343.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2036.2011.04988.x","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis","volume":"35","author":"Triantos","year":"2012","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD011343.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0168-8278(96)80293-5","article-title":"Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response","volume":"25","author":"Meeberg","year":"1996","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0168-8278(98)80059-7","article-title":"Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses","volume":"29","author":"Hoogstraten","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD011343.pub2-BIB0075|cit75","first-page":"401a","article-title":"Ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis (PSC): results of a 2-year randomized controlled trial evaluating single versus multiple daily doses","volume":"26","author":"Hoogstraten","year":"1997","journal-title":"Hepatology"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD011343.pub2-BIB0076|cit76","first-page":"A 7","article-title":"Single versus three times daily ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis (PSC): results of a randomized controlled trial","volume":"8","author":"Hoogstraten","year":"1996","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0077|cit77","first-page":"647A","article-title":"Treatment with budesonide or prednisone in combination with ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): a randomized controlled pilot study","volume":"28","author":"Vleggaar","year":"1998","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0168-8278(98)80059-7","article-title":"Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses","volume":"29","author":"Hoogstraten","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0079|cit79","first-page":"A1352","article-title":"Single versus three times daily ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis (PSC): results of a randomized controlled trial","volume":"110","author":"Hoogstraten","year":"1996","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0080|cit80","first-page":"1089","article-title":"Ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis (PSC): results of a 2-year randomized controlled trial evaluating single versus multiple daily doses","volume":"26","author":"Hoogstraten","year":"1997","journal-title":"Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD011343.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/j.1572-0241.2000.02267.x","article-title":"Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group","volume":"95","author":"Hoogstraten","year":"2000","journal-title":"The American Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD011343.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/j.1572-0241.2000.02267.x","article-title":"Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group","volume":"95","author":"Hoogstraten","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0083|cit83","first-page":"A62","article-title":"Ursodeoxycholic acid (UDCA) therapy for primary sclerosing cholangitis (PSC) - preliminary report of a randomized controlled trial","volume":"16","author":"Vanthiel","year":"1992","journal-title":"Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD011343.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.amjmed.2005.05.031","article-title":"Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases","volume":"118","author":"Villamil","year":"2005","journal-title":"The American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00042737-200102000-00013","article-title":"No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study","volume":"13","author":"Vleggaar","year":"2001","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0086|cit86","first-page":"563A","article-title":"No beneficial effects of transdermal nicotine in primary sclerosing cholangitis (PSC): results of a randomized double-blind cross-over study","volume":"30","author":"Vleggaar","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0087|cit87","first-page":"A767","article-title":"No beneficial effects of probiotics in primary sclerosing cholarigitis (PSC): a randomized placebo-controlled cross-over study","volume":"132","author":"Vleggaar","year":"2007","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD011343.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/MEG.0b013e3282f5197e","article-title":"Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study","volume":"20","author":"Vleggaar","year":"2008","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD011343.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"A67","DOI":"10.1097\/MEG.0b013e3282f5197e","article-title":"No beneficial effects of probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover study","volume":"20","author":"Vleggaar","year":"2008","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"7725","key":"10.1002\/14651858.CD011343.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0140-6736(71)80107-1","article-title":"Azathioprine treatment in primary sclerosing cholangitis","volume":"2","author":"Wagner","year":"1971","journal-title":"Lancet"},{"issue":"24","key":"10.1002\/14651858.CD011343.pub2-BIB0091|cit91","first-page":"42","article-title":"Primary sclerosing cholangitis. To slow progression and reduce carcinoma risk","volume":"148","author":"Anonymous","year":"2006","journal-title":"MMW Fortschritte der Medizin"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0092|cit92","unstructured":"Randomised trial of low dose, medium dose and high dose ursodeoxycholic acid with placebo in primary sclerosing cholangitis http:\/\/isrctn.com\/ISRCTN16531030"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0093|cit93","unstructured":"Trial of high-dose urso in primary sclerosing cholangitis http:\/\/clinicaltrials.gov\/show\/NCT00059202"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0094|cit94","unstructured":"Randomized double-blind placebo-controlled trial to evaluate the efficacy of N-acetylcystein in patients with chronic pancreatitis and primary sclerosing cholangitis. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-004170-26"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0095|cit95","unstructured":"A phase 3, open-label, randomized, prospective clinical trial evaluating the efficacy of stratified treatment with ursodeoxycholic acid (UDCA) in preventing hepatobiliary and colorectal malignancy in surveillance patients with primary sclerosing cholangitis (PSC) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-003310-24\/SE"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0096|cit96","unstructured":"A phase 2, randomized, double blind, placebo controlled, parallel group, multiple center study to evaluate the safety, tolerability, and efficacy of NGM282 administered for 12 weeks in patients with primary sclerosing cholangitis (PSC) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-003392-30\/GB\/"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0097|cit97","unstructured":"Simtuzumab (GS-6624) in the prevention of progression of liver fibrosis in subjects with primary sclerosing cholangitis (PSC) http:\/\/clinicaltrials.gov\/show\/NCT01672853"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0098|cit98","unstructured":"Mitomycin C therapy for patients with primary sclerosing cholangitis http:\/\/clinicaltrials.gov\/show\/NCT01688024"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0099|cit99","unstructured":"Norursodeoxycholic acid in the treatment of primary sclerosing cholangitis NUC-3 http:\/\/clinicaltrials.gov\/show\/NCT01755507"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0100|cit100","unstructured":"Obeticholic acid (OCA) in primary sclerosing cholangitis (PSC) https:\/\/clinicaltrials.gov\/show\/NCT02177136"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0101|cit101","unstructured":"Phase 2 study of NGM282 in patients with primary sclerosing cholangitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02704364"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0102|cit102","unstructured":"Safety, tolerability, and efficacy of GS\u00ad9674 in adults with primary sclerosing cholangitis without cirrhosis (PSC\u00adphase 2) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02943460"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0103|cit103","unstructured":"Efficacy and safety of vedolizumab intravenous (IV) in the treatment of primary sclerosing cholangitis in subjects with underlying inflammatory bowel disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03035058"},{"issue":"5","key":"10.1002\/14651858.CD011343.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD011343.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"10","key":"10.1002\/14651858.CD011343.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PloS One"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"Spirit 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"21","key":"10.1002\/14651858.CD011343.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.3748\/wjg.14.3350","article-title":"Etiopathogenesis of primary sclerosing cholangitis","volume":"14","author":"Chapman","year":"2008","journal-title":"World Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD011343.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"e63509","DOI":"10.1371\/journal.pone.0063509","article-title":"Efficacy of new generation antidepressants: differences seem illusory","volume":"8","author":"Re","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0114|cit114","unstructured":"Dias S Sutton AJ Welton NJ Ades AE NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment, September 2011 (last updated April 2012) www.nicedsu.org.uk\/TSD3%20Heterogeneity.final%20report.08.05.12.pdf"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0115|cit115","unstructured":"Dias S Welton NJ Sutton AJ Ades AE NICE DSU Technical Support Document 1: Introduction to evidence synthesis for decision making, April 2011 (last updated April 2012) www.nicedsu.org.uk\/TSD1%20Introduction.final.08.05.12.pdf"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0116|cit116","unstructured":"Dias S Welton NJ Sutton AJ Ades AE NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials, August 2011 (last updated April 2014) http:\/\/www.nicedsu.org.uk\/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0117|cit117","unstructured":"Dias S Welton NJ Sutton AJ Caldwell DM Lu G Ades AE NICE DSU Technical Support Document 4: Inconsistency in networks of evidence based on randomised controlled trials, May 2011 (last updated April 2014) http:\/\/www.nicedsu.org.uk\/TSD4%20Inconsistency.final.15April2014.pdf"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL clinical practice guidelines: management of cholestatic liver diseases","volume":"51","author":"European Association for the Study of the Liver","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"7109","key":"10.1002\/14651858.CD011343.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/B:DDAS.0000011827.87103.2e","article-title":"A pilot study of etanercept in the treatment of primary sclerosing cholangitis","volume":"49","author":"Epstein","year":"2004","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0121|cit121","unstructured":"EuroQol About EQ-5D http:\/\/www.euroqol.org\/about-eq-5d.html"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0122|cit122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004036.pub3","article-title":"Glucocorticosteroids for primary sclerosing cholangitis","author":"Giljaca","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0123|cit123","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2013, Issue 7. Art. No.: LIVER"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000347207","article-title":"Liver transplantation for perihilar cholangiocarcinoma","volume":"31","author":"Gores","year":"2013","journal-title":"Digestive Diseases"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0016-5085(85)90326-9","article-title":"Abnormalities in tests of copper metabolism in primary sclerosing cholangitis","volume":"89","author":"Gross","year":"1985","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0127|cit127","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0129|cit129","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/SLA.0b013e318204e658","article-title":"Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis","volume":"253","author":"Jay","year":"2011","journal-title":"Annals of Surgery"},{"issue":"11","key":"10.1002\/14651858.CD011343.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004182.pub3","article-title":"D-penicillamine for primary sclerosing cholangitis","author":"Klingenberg","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011343.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00423-014-1214-6","article-title":"Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era","volume":"399","author":"Klose","year":"2014","journal-title":"Langenbecks Archives of Surgery"},{"issue":"12","key":"10.1002\/14651858.CD011343.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11894-013-0361-1","article-title":"Role of endoscopy in primary sclerosing cholangitis","volume":"15","author":"Koro","year":"2013","journal-title":"Current Gastroenterology Reports"},{"issue":"6","key":"10.1002\/14651858.CD011343.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ng.2616","article-title":"Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis","volume":"45","author":"Liu","year":"2013","journal-title":"Nature Genetics"},{"issue":"474","key":"10.1002\/14651858.CD011343.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1198\/016214505000001302","article-title":"Assessing evidence inconsistency in mixed treatment comparisons","volume":"101","author":"Lu","year":"2006","journal-title":"Journal of the American Statistical Association"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/sim.698","article-title":"A comparison of methods to detect publication bias in meta-analysis","volume":"20","author":"Macaskill","year":"2001","journal-title":"Statistics in Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011343.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/2012.jama.11228","article-title":"How to use an article reporting a multiple treatment comparison meta-analysis","volume":"308","author":"Mills","year":"2012","journal-title":"JAMA"},{"issue":"9128","key":"10.1002\/14651858.CD011343.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0142|cit142","unstructured":"NCBI Cholangitis, Sclerosing http:\/\/www.ncbi.nlm.nih.gov\/mesh\/68015209"},{"issue":"5","key":"10.1002\/14651858.CD011343.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ije\/21.5.837","article-title":"Intention-to-treat analysis: implications for quantitative and qualitative research","volume":"21","author":"Newell","year":"1992","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cld.2007.11.011","article-title":"Role of methotrexate in the treatment of chronic cholestatic disorders","volume":"12","author":"Novak","year":"2008","journal-title":"Clinics in Liver Disease"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2006-933559","article-title":"Etiopathogenesis of primary sclerosing cholangitis","volume":"26","author":"O'Mahony","year":"2006","journal-title":"Seminars in Liver Disease"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0146|cit146","unstructured":"Members of OpenBUGS Project Management Group OpenBUGS 2014"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011343.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jamcollsurg.2007.12.015","article-title":"Primary sclerosing cholangitis: role of extrahepatic biliary resection","volume":"206","author":"Pawlik","year":"2008","journal-title":"Journal of the American College of Surgeons"},{"issue":"14","key":"10.1002\/14651858.CD011343.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an international PSC study group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0151|cit151","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003626.pub2","article-title":"Bile acids for primary sclerosing cholangitis","author":"Poropat","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0153|cit153","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"35","key":"10.1002\/14651858.CD011343.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD011343.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011343.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"Schulz","year":"2010","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0161|cit161","unstructured":"StataCorp LP Stata\/SE 14.2 for Windows[64-bit x86-64] 2017"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.suc.2014.01.008","article-title":"Iatrogenic biliary injuries: identification, classification, and management","volume":"94","author":"Stewart","year":"2014","journal-title":"Surgical Clinics of North America"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.27180","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?)","volume":"60","author":"Tabibian","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1053\/bega.2001.0205","article-title":"Natural history and prognostic models in primary sclerosing cholangitis","volume":"15","author":"Talwalkar","year":"2001","journal-title":"Best Practice & Research: Clinical Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD011343.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1572-0241.2005.40484.x","article-title":"Mycophenolate mofetil for the treatment of primary sclerosing cholangitis","volume":"100","author":"Talwalkar","year":"2005","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0166|cit166","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User Manual for Trial Sequential Analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark www.ctu.dk\/tsa 2011 1 115"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/2046-4053-1-41","article-title":"Sample size and power considerations in network meta-analysis","volume":"1","author":"Thorlund","year":"2012","journal-title":"Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011343.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2036.2011.04822.x","article-title":"Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis","volume":"34","author":"Triantos","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0169|cit169","unstructured":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen TSA version 0.9 2011"},{"issue":"3","key":"10.1002\/14651858.CD011343.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"International Journal of Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/egh.12.20","article-title":"Management of perihilar cholangiocarcinoma in the era of multimodal therapy","volume":"6","author":"Valero","year":"2012","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011343.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"Valkenhoef","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD011343.pub2-BIB0173|cit173","unstructured":"Ware JE SF-36\u00ae Health Survey Update http:\/\/www.sf-36.org\/tools\/sf36.shtml"},{"issue":"1","key":"10.1002\/14651858.CD011343.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7644","key":"10.1002\/14651858.CD011343.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD011343.pub2-BIB0176|cit176","first-page":"31","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis","volume":"60","author":"Wunsch","year":"2014","journal-title":"Hepatology"},{"issue":"4-5","key":"10.1002\/14651858.CD011343.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.autrev.2014.01.040","article-title":"Diagnosis and classification of primary sclerosing cholangitis","volume":"13","author":"Yimam","year":"2014","journal-title":"Autoimmunity Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011343.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T09:00:20Z","timestamp":1710838820000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011343.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,28]]},"references-count":177,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011343.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,28]]}}}